New pill PG-033 tested for safety in first human trial
NCT ID NCT07619183
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial will test the safety and tolerability of multiple doses of PG-033 tablets in 30 healthy adults. Participants will be randomly assigned to receive either PG-033 or a placebo. The study aims to find out how the drug moves through the body and whether it causes any side effects. If successful, it could lead to further research on PG-033 as a treatment for lichen simplex chronicus, a condition that causes intense itching and thickened skin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PG-033 tablets
- What this could lead to
- If this early safety study goes well, it could pave the way for larger trials testing PG-033 as a treatment for lichen simplex chronicus, a chronic itchy skin condition.
- What could go wrong
- This is a very early Phase 1 trial with only 30 healthy participants, so it cannot yet show if PG-033 actually helps the disease. The drug may prove unsafe or ineffective in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LICHEN SIMPLEX CHRONICUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Shijitan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100038, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.